TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT03526835: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Sponsor: Merus B.V. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 560 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT03526835 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03526835 Rescue Dossier →